Prognostic Markers in Tumors with Psammoma Bodies

Introduction to Prognostic Markers

The presence of psammoma bodies in tumors is associated with significant prognostic value, with serum lactate dehydrogenase (LDH) being a key marker, as it correlates with tumor burden, treatment response, and survival in patients with psammoma body-containing tumors 1, 2

LDH is the marker with established prognostic significance in cases with psammoma bodies, reflecting tumor cell turnover and indicating ongoing disease activity even when imaging studies show regression, with elevated levels associated with poorer outcomes 2
Elevated LDH levels are associated with poorer outcomes and can be used to monitor disease progression and treatment response in patients with tumors characterized by psammoma bodies 3

Serial measurements of LDH should be performed to monitor disease progression and treatment response in patients with psammoma body-containing tumors, with a rising LDH level indicating potential disease progression or treatment failure 2
The Chemotherapy Response Score (CRS) system, which considers the presence of psammoma bodies, can be used alongside LDH measurements to assess treatment response in patients with psammoma body-containing tumors 1, 2

In ovarian serous carcinomas, LDH levels together with the presence of psammoma bodies can help predict response to chemotherapy and overall survival, according to the American Society of Clinical Oncology 1, 2
In meningiomas with psammoma bodies, LDH can serve as a marker for monitoring recurrence, as recommended by the National Comprehensive Cancer Network 3

When evaluating prognostic markers in tumors with psammoma bodies, it's essential to consider the specific tumor type, stage, and treatment history, as suggested by the National Cancer Institute 4
Multiple measurements of LDH over time provide more valuable prognostic information than a single determination, with high levels of evidence supporting the use of LDH as a prognostic marker in tumors with psammoma bodies 3